Table 2.
Imaging and explant characteristics of patients with hepatocellular carcinoma.
| All patients with HCC (n = 63) | TACE (n = 18) | Ablation | |||
|---|---|---|---|---|---|
| Imaging prior to bridging therapy | |||||
| Imaging type | MRI | 37 (86.0%) | 15 (83.3%) | 21 (84.0%) | p = 0.823 |
| CT | 4 (9.3%) | 2 (11.1%) | 2 (8.0%) | ||
| Number tumors median | 1.5 | 1 | 1 | p = 0.014 | |
| Largest tumor dimension median (cm) | 2.7 | 2.9 | 2.3 | p = 0.149 | |
| Imaging after bridging therapy | |||||
| Imaging type | MRI | 37 (86.0%) | 13 (76.5%) | 23 (95.8%) | p = 0.134 |
| CT | 1 (2.3%) | 1 (5.9%) | 0 (0.0%) | ||
| Post-bridge imaging with HCC | Yes | 9 (23.7%) | 6 (40.0%) | 3 (13.0%) | p = 0.104 |
| No | 29 (67.4%) | 9 (60.0%) | 20 (87.0%) | ||
| Explant – patients grouped on first bridging procedure | |||||
| Viable tumor on explant | Yes | 50 (79.4%) | 11 (61.1%) | 21 (84.0%) | p = 0.069 |
| No | 13 (20.6%) | 7 (38.9%) | 4 (16.0%) | ||
| Number of tumors on explant pathology | 0 | 3 (4.8%) | 1 (5.6%) | 1 (4.0%) | p = 0.642 |
| 1 | 32 (50.8%) | 6 (33.3%) | 15 (60.0%) | ||
| 2 | 13 (20.6%) | 6 (33.3%) | 5 (40.0%) | ||
| 3 | 13 (20.6%) | 4 (22.2%) | 3 (12.0%) | ||
| 4 | 2 (3.2%) | 1 (5.6%) | 1 (4.0%) | ||
| Explant tumor necrosis | Yes | 39 (62.9%) | 12 (66.7%) | 20 (80.0%) | p = 0.482 |
| No | 23 (37.1%) | 6 (33.3%) | 5 (20.0%) | ||
| Explant tumor necrosis, mean (SD) | 34.39% | 41.20% | 47.00% | p = 0.787 | |
| Explant pathology T-stage | TO | 3 (4.8%) | 2 (11.1%) | 1 (4.0%) | p = 0.198 |
| T1 | 27 (42.9%) | 4 (22.2%) | 13 (52.0%) | ||
| T2 | 23 (36.5%) | 8 (44.4%) | 6 (24.0%) | ||
| T3a | 2 (3.2%) | 0 (0.00%) | 2 (8.0%) | ||
| None | 8 (12.7%) | 4 (22.2%) | 3 (12.0%) | ||
| Tumor grade | 1 | 12 (24.5%) | 2 (20.0%) | 1 (4.8%) | p = 0.346 |
| 2 | 26 (53.1%) | 6 (60.0%) | 13 (61.9%) | ||
| 3 | 9 (18.4%) | 2 (20.0%) | 5 (23.8%) | ||
| Explant largest tumor diameter in cm, mean (SD) | 2.8 | 2.4 | 3.8 | p = 0.141 | |